Actively Recruiting

Phase 1
Age: 19Years - 64Years
All Genders
Healthy Volunteers
NCT07265466

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Led by Onconic Therapeutics Inc. · Updated on 2025-12-04

96

Participants Needed

1

Research Sites

19 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

CONDITIONS

Official Title

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Who Can Participate

Age: 19Years - 64Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy subjects aged 19 years to under 65 years at screening
  • Subjects weighing at least 50 kg (or at least 45 kg for females) with a BMI between 18.0 and 30.0 kg/m2
  • Subjects who have voluntarily agreed to participate and provided written informed consent after understanding the trial details
Not Eligible

You will not qualify if you...

  • History of significant disease in liver, kidneys, digestive, respiratory, musculoskeletal, endocrine, neuropsychiatric, hematopoietic, oncological, or cardiovascular systems
  • History of significant bleeding or bleeding disorders such as hemophilia
  • History of gastrointestinal disorders (e.g., Crohn's disease, ulcerative disease) or surgeries affecting drug absorption (excluding appendectomy, hernia repair, endoscopic polypectomy, hemorrhoidectomy, fissure, or fistula surgery)
  • Presence of hereditary disorders like galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  • Abnormal laboratory test results on screening
  • Judged unsuitable for study participation by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cha University Bundang Medical Center

Seongnam-si, Gyeonggi-do, South Korea, 13496

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

FACTORIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban | DecenTrialz